Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome
Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome: A Non-randomized Prospective Trial (The BOOST Study)
Children's Mercy Hospital Kansas City
40 participants
Jul 31, 2025
INTERVENTIONAL
Conditions
Summary
This is a single-site open label non-randomized study comparing effects of sequential versus continuous use of progesterone supplementation amongst Turner Syndrome (TS) patients with primary ovarian insufficiency (POI) prescribed hormone replacement therapy (HRT).
Eligibility
Inclusion Criteria4
- Diagnosis of Turner Syndrome and Primary Ovarian Insufficiency.
- Prescribed adult dosing\* of transdermal or oral estradiol for estrogen replacement therapy.
- \*Adult dosing of will be defined per published clinical practice guidelines from the 2023 International Turner Syndrome Meeting (i.e. 50-200μg/day of transdermal estradiol, or (i.e. 50-200μg/day of transdermal estradiol or 2-4mg/day oral estradiol).
- Have achieved menarche.
Exclusion Criteria4
- Disclosure of sexual activity and desire for contraception.
- Having a levonorgestrel-releasing intrauterine device or etonogestrel arm implant in place.
- Having received depot medroxyprogesterone within one year prior to study recruitment.
- Non-English or non-Spanish speaking.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral micronized progesterone 200mg for the first 12 days of a 30 to 31-day cycle
Oral micronized progesterone 100mg daily taken throughout the 30 to 31-day cycle.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06834594